SEELQ — Seelos Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $0.00m
- $9.82m
- $2.20m
Annual income statement for Seelos Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.375 | 0 | 0 | 0 | 2.2 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 30.1 | 18.8 | 63.9 | 70.9 | 51.9 |
| Operating Profit | -29.7 | -18.8 | -63.9 | -70.9 | -49.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -51.3 | -19.1 | -66 | -73.5 | -37.9 |
| Net Income After Taxes | -51.3 | -19.1 | -66 | -73.5 | -37.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -51.3 | -19.1 | -66 | -73.5 | -37.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -51.3 | -19.1 | -66 | -73.5 | -37.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -9,692 | -1,639 | -2,696 | -2,656 | -750 |